Never Miss a Potential Recovery Again

Sign up for Class
Action Alerts

Each year, class action lawsuits generate billions of dollars in settlement funds, but many shareholders fail to file a claim. Stay in the know regarding class action lawsuits by signing up for alerts.

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit. No spam will be sent to your email.

Track Your Future Recoveries Withsnaptrade iconConnect Account

We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

5

Days Left

CMBM

Cambium Networks Corporation

Deadline

July 22 2024

Class Period

5/8/23 - 1/18/24

Allegations

(1) there was a buildup of inventory in the Company’s distribution channels; (2) the Company and its distributors were reasonably likely to offer aggressive discounts to reduce the high channel inventories; (3) the Company’s revenue would decline sequentially until the excess channel inventory was sold through; (4) Cambium was likely to incur significant charges to writedown excess and obsolete inventory; (5) as a result of the foregoing, the Company’s fiscal 2023 revenue and earnings would be adversely affected; and (6) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/8/23 - 1/18/24

Deadline

July 22 2024

Learn More

5

Days Left

BIIB

Biogen Inc.

Deadline

July 22 2024

Class Period

2/3/22 - 2/13/24

Allegations

(i) Biogen had overstated its efforts to enhance its transparency, corporate governance, and compliance controls and procedures, as well as the efficacy of those controls and procedures; (ii) accordingly, Biogen maintained inadequate compliance controls and procedures in connection with its business operations in foreign countries; (iii) Biogen and/or its employees were engaged in unlawful or otherwise improper conduct in several foreign countries; (iv) the foregoing subjected the Company to a heightened risk of governmental and/or regulatory scrutiny and enforcement action, as well as significant legal, financial, and reputational harm; (v) Biogen overstated the strength of its Alzheimer’s disease related product portfolio, including the its joint efforts and success with pharmaceutical company, Eisai, in launching and providing access to Leqembi; (vi) Biogen also downplayed the negative impact that the Reata Acquisition would have on its FY 2023 non-GAAP diluted EPS; (vii) all the foregoing were likely to have a significant negative impact on Biogen’s 2023 results; and (viii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/3/22 - 2/13/24

Deadline

July 22 2024

Learn More

6

Days Left

FSLY

Fastly, Inc.

Deadline

July 23 2024

Class Period

2/15/24 - 5/1/24

Allegations

(i) contrary to its representations to investors, Fastly was in fact experiencing a significant deceleration in growth among its largest customers and was losing the increased market share it had gained as a result of the 2023 content delivery network consolidation trend; (ii) the foregoing issues were likely to have a material negative impact on the Company’s revenue growth; (iii) accordingly, the Company was unlikely to meet its own previously issued revenue guidance for FY 2024; (iv) as a result, the Company’s financial position and/or prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/15/24 - 5/1/24

Deadline

July 23 2024

Learn More

12

Days Left

ENPH

Enphase Energy, Inc.

Deadline

July 29 2024

Class Period

2/7/23 - 4/25/23

Allegations

According to the complaint, on April 25, 2023, Enphase issued a press release announcing its first quarter earnings. In pertinent part, defendants announced revenue in the United States had decreased by approximately 9% attributing it to macroeconomic conditions. Additionally, defendants put out a weak second quarter outlook for 2023 where revenue was estimated to be within the range of $700 million to $750 million. Following this news, the price of Enphase’s common stock declined dramatically. From a closing market price of $220.60 per share on April 25, 2023, Enphase’s stock price fell to $163.83 per share on April 26, 2023, a decline of nearly 26% in the span of just a single day.

Class Period

2/7/23 - 4/25/23

Deadline

July 29 2024

Learn More

13

Days Left

RIVN

Rivian Automotive, Inc.

Deadline

July 30 2024

Class Period

8/12/22 - 2/21/24

Allegations

(i) Rivian had overstated demand for its products, as well as its ability to withstand negative, near-term macroeconomic impacts; (ii) accordingly, Rivian’s business was experiencing reduced demand and increased customer cancellations as a result of, inter alia, high interest rates; (iii) as a result, Rivian’s order bank had significantly deteriorated; (iv) all the foregoing was likely to, and did, negatively impact the Company’s anticipated earnings and vehicle production targets for 2024; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

8/12/22 - 2/21/24

Deadline

July 30 2024

Learn More

13

Days Left

HTZ

Hertz Global Holdings, Inc.

Deadline

July 30 2024

Class Period

4/27/23 - 4/24/24

Allegations

(i) Hertz had downplayed the financial impact of vehicle depreciation, and/or overstated its ability to track and manage vehicle depreciation; (ii) demand for Hertz’s EVs was not as strong as Defendants had led investors to believe; (iii) Hertz had too many vehicles, particularly EVs, in its fleet to remain profitable; (iv) as a result of all the foregoing, Hertz was likely to incur significant losses on the disposition of both its ICE vehicles and EVs; (v) all the foregoing was likely to, and did, have a significant negative impact on Hertz’s financial results; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

4/27/23 - 4/24/24

Deadline

July 30 2024

Learn More

16

Days Left

HUM

Humana Inc.

Deadline

August 2 2024

Class Period

7/27/22 - 1/24/24

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: Specifically, defendants downplayed pressures on the Company’s adjusted earnings per share, resulting from increased medical costs associated with pent-up demand for healthcare procedures which contrary to the Company’s assurances, resulted in increased utilization rates and costs.

Class Period

7/27/22 - 1/24/24

Deadline

August 2 2024

Learn More

19

Days Left

SMG

The Scotts Miracle-Gro Company

Deadline

August 5 2024

Class Period

11/3/21 - 8/1/23

Allegations

According to the filed complaint, defendants made false statements and/or concealed that Scotts had an oversupply of inventory that far exceeded consumer demand. Recognizing that problem, Scotts executives engaged in a scheme to saturate the Company’s sales channel with more product than those retailers could sell through to end users, a practice that required Scotts sales personnel to pressure retailers to purchase more inventory than they wanted or needed. Ultimately, Scotts was only able to satisfy the covenants through the channel stuffing scheme.

Class Period

11/3/21 - 8/1/23

Deadline

August 5 2024

Learn More

19

Days Left

MRNS

Marinus Pharmaceuticals, Inc.

Deadline

August 5 2024

Class Period

3/17/21 - 5/7/24

Allegations

(1) defendants understated the risk of failure to meet the early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

3/17/21 - 5/7/24

Deadline

August 5 2024

Learn More

20

Days Left

GRTS

Gritstone bio, Inc.

Deadline

August 6 2024

Class Period

3/9/23 - 2/29/24

Allegations

(i) the Company would be unable to launch the Phase 2b CORAL Study, it's approved COVID-19 vaccine, in the timeframe it had represented to investors; (ii) the foregoing would impair Gritstone’s ability to obtain external funding in connection with the Study, thereby negatively affecting Gritstone’s ability to maintain its balance sheet and cash position; (iii) accordingly, Gritstone overstated its ability to successfully develop and commercialize its products; (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

3/9/23 - 2/29/24

Deadline

August 6 2024

Learn More

26

Days Left

LW

Lamb Weston Holdings, Inc.

Deadline

August 12 2024

Class Period

7/25/23 - 4/3/24

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: In truth, defendants knew of, or recklessly disregarded, problems associated with the Enterprise Resource Planning (ERP) system that would hinder its successful implementation. Despite those issues, Lamb Weston pushed ahead with its implementation of an ERP system that was not ready to go live, knowing that a premature roll-out would have a material negative impact on the Company’s business and operations. As a result, the statements concerning its business, operations, and prospects, including its financial guidance for fiscal 2024, lacked a reasonable factual basis. In addition, to the extent the Company purported to warn of risks regarding the negative impacts from an unsuccessful implementation of the ERP system, defendants omitted that such risks had already begun to materialize.

Class Period

7/25/23 - 4/3/24

Deadline

August 12 2024

Learn More

26

Days Left

TWOU

2U, Inc.

Deadline

August 12 2024

Class Period

2/9/22 - 2/12/24

Allegations

(1) the Company was unable to sustain relationships with key universities and organizations; (2) as a result, certain degree programs and partnerships failed to materialize or were cancelled; (3) the Company’s transition to a platform company would lead to a decrease in full course equivalent enrollments; (4) accordingly, the Company had overstated the stability and/or longevity of its contractual agreements and/or revenue sources; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/9/22 - 2/12/24

Deadline

August 12 2024

Learn More

26

Days Left

RBLX

Roblox Corporation

Deadline

August 12 2024

Class Period

11/15/23 - 5/8/24

Allegations

According to the complaint, on February 7, 2024, Roblox – the publisher of the Minecraft video game – issued its FY 2024 fiscal guidance. It was the first time Roblox issued a fiscal guidance to investors. Then, on May 9, 2023, Roblox hosted its quarterly earnings call and slashed its guidance for FY 2024. Management blamed changes in player engagement for the guidance reduction. Analysts expressed dismay at the rapidly reduced guidance, with one analyst noting Roblox made the cut “at one of its first real opportunities to do so.” Other analysts reported the reduced guidance “may raise concerns regarding management’s visibility into core bookings growth” and the Company “will be burdened by a management credibility issue over the near term.” Following the earnings call, RBLX shares fell $8.61, or 22% overnight.

Class Period

11/15/23 - 5/8/24

Deadline

August 12 2024

Learn More

27

Days Left

TDC

Teradata Corporation

Deadline

August 13 2024

Class Period

2/13/23 - 2/12/24

Allegations

(i) under Teradata’s expanded business model, which involved engagement with additional customer business units and decisionmakers, transactions with the Company’s customers took longer to finalize; (ii) Teradata thus overstated its ability to close customer transactions within their intended timeframes under its expanded business model; (iii) Terada failed to timely close several customer transactions that it had factored into its outlook for 2023 Annual Recurring Revenue (ARR) growth; (iv) as a result, the Company was unlikely to meet its full year 2023 total and public cloud ARR expectations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/13/23 - 2/12/24

Deadline

August 13 2024

Learn More

33

Days Left

PATH

UiPath, Inc.

Deadline

August 19 2024

Class Period

12/1/23 - 5/29/24

Allegations

According to the complaint, it alleges that throughout the Class Period, defendants made materially false and misleading statements concerning the success of UiPath’s turnaround strategy. For instance, defendants represented that the Company was “executing against that strategy, and we’re seeing [the] results in the deal quality and the customer quality,” asserted that “our strategic investments in innovations and our go-to-market ecosystem positions us well for continued momentum,” and that “there’s no doubt there’s [been] better execution” since the implementation of the turnaround strategy.

Class Period

12/1/23 - 5/29/24

Deadline

August 19 2024

Learn More

33

Days Left

NKE

NIKE, Inc.

Deadline

August 19 2024

Class Period

3/19/21 - 3/21/24

Allegations

(1) NIKE’s direct-to-consumer strategy was unable to generate sustainable revenue growth; (2) NIKE’s purported competitive advantages were unable to protect the Company from intense competitive pressures after NIKE largely disengaged from many of its wholesale and retail partners to focus on the Company’s direct-to-consumer strategy; and (3) as a result, defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Class Period

3/19/21 - 3/21/24

Deadline

August 19 2024

Learn More

37

Days Left

FF

FutureFuel Corp.

Deadline

August 23 2024

Class Period

8/10/23 - 5/10/24

Allegations

(1) FutureFuel did not have adequate internal controls; (2) FutureFuel’s financial statements were misstated; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

8/10/23 - 5/10/24

Deadline

August 23 2024

Learn More

37

Days Left

TM

Toyota Motor Corporation

Deadline

August 23 2024

Class Period

6/23/22 - 6/2/24

Allegations

(1) Toyota understated its malfeasance relating to certification of its cars and issues relating to overall legal compliance; and (2) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

6/23/22 - 6/2/24

Deadline

August 23 2024

Learn More

44

Days Left

SRG

Seritage Growth Properties

Deadline

August 30 2024

Class Period

7/7/22 - 5/10/24

Allegations

(1) the Company lacked effective internal controls regarding the identification and review of impairment indicators for investments in real estate; (2) as a result, the Company had overstated the value and projected gross proceeds of certain real estate assets; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

7/7/22 - 5/10/24

Deadline

August 30 2024

Learn More

54

Days Left

MDB

MongoDB, Inc.

Deadline

September 9 2024

Class Period

8/31/23 - 5/30/24

Allegations

According to the complaint, on March 7, 2024, MongoDB reported strong Q4 2024 results and then announced lower than expected full-year guidance for 2025. MongoDB attributed it to the Company’s change in its “sales incentive structure” which led to a decrease in revenue related to “unused commitments and multi-year licensing deals.” Following this news, MongoDB’s stock price fell by $28.59 per share to close at $383.42 per share. Later, on May 30, 2024, MongoDB further lowered its guidance for the full year 2025 attributing it to “macro impacting consumption growth.” Analysts commenting on the reduced guidance questioned if changes made to the Company’s marketing strategy “led to change in customer behavior and usage patterns.” Following this news, MongoDB’s stock price fell by $73.94 per share to close at $236.06 per share.

Class Period

8/31/23 - 5/30/24

Deadline

September 9 2024

Learn More

55

Days Left

CVS

CVS Health Corporation

Deadline

September 10 2024

Class Period

5/3/23 - 4/30/24

Allegations

(i) the forecasts CVS used to determine plan premiums were ineffective at accounting for medical cost trends and health care utilization patterns; (ii) as a result, CVS was likely to incur significant expenses to cover cost increases that were not accounted for in the Company’s forecasts and thus not covered by plan premiums; (iii) accordingly, CVS had overstated the profitability of its health care benefits segment; (iv) contrary to defendants’ assurances, the revenues generated from the Company’s other primary segments were insufficient to offset the negative financial impact of the increasing expenditures within the health care benefits segment; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

5/3/23 - 4/30/24

Deadline

September 10 2024

Learn More

55

Days Left

WBA

Walgreens Boots Alliance, Inc.

Deadline

September 10 2024

Class Period

10/12/23 - 6/26/24

Allegations

According to the complaint, on June 27, 2024, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024. The Company attributed its results and lowered guidance on the “significant challenges in the U.S. Retail Pharmacy business stemming from a worse-than-expected consumer environment and challenging pharmacy industry trends.” Following this news, Walgreens stock began trading more than 20% lower than the previous day’s closing price of $15.65 per share.

Class Period

10/12/23 - 6/26/24

Deadline

September 10 2024

Learn More

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

Innoviz Shareholders will be Represented by Levi & Korsinsky & Pomerantz
Lucid Alternative Fund, LP v. Innoviz Technologies Ltd., et al., 1:24-cv-01971-AT is a lawsuit currently pending in the United States District Court for the Southern District of New York. The action was filed on behalf of investors in Innoviz Technologies Ltd. (NASDAQ: INVZ) who allegedly suffered losses due to securities fraud by the company. On...Read more

June 7, 2024

Learn More

Levi & Korsinsky Ranked Among the Top 50 Plaintiffs' Firms of 2023
Levi & Korsinsky (“L&K”) has once again been recognized by Institutional Shareholder Services Securities Class Action Services (“ISS SCAS”) as one of the top 50 plaintiffs’ firms in the United States, recovering over $133 million for investors in securities-related class action settlements in 2023. On April 22, 2024, ISS SCAS released its “Top Plaintiff Law...Read more

May 14, 2024

Learn More

Lantronix, Inc. Lawsuit Proceeds with Selection of Co-Lead Plaintiffs
Neilsen v. Lantronix, Inc., et al., 8:24-cv-00385-FWS-JDE is a lawsuit currently pending in the United States District Court for the Central District of California. The action was filed on behalf of investors in Lantronix, Inc. (NASDAQ: LTRX) who allegedly suffered losses due to securities fraud by the company. On May 7, 2024, United States District...Read more

May 13, 2024

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys